Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: Implications for targeted therapeutics

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 659-667

  Toman, Inka ^a   Loree, Jonathan ^a   Klimowicz, Alexander C ^b   Bahlis, Nizar ^b   Lai, Raymond ^a   Belch, Andrew ^a   Pilarski, Linda ^a   Reiman, Tony ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bob1; Multiple myeloma; Oct2; prognosis

Indexed keywords

MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 2; SYNDECAN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BOB 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FLUORESCENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; ORGANIC CATION TRANSPORT PROTEINS; PLASMA CELLS; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; SYNDECAN-1; TRANS-ACTIVATORS;

EID: 79953175301     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.548535     Document Type: Article

References (20)

1. Scheidereit C, Heguy A, Roeder RG. Identification and purification of a human lymphoid-specific octamer-binding protein (OTF-2) that activates transcription of an immuno-globulin promoter in vitro. Cell 1987;51:783-793.
2. Staudt LM, Singh H, Sen R, Wirth T, Sharp PA, Baltimore D. A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature 1986;323:640-643. (Pubitemid 16008559)
3. Gstaiger M, Knoepfel L, Georgiev O, Schaffner W, Hovens CM. A B-cell coactivator of octamer-binding transcription factors. Nature 1995;373:360-362.
4. Luo Y, Fujii H, Gerster T, Roeder RG. A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors. Cell 1992;71:231-241.
5. Strubin M, Newell JW, Matthias P. OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 1995;80:497-506.
6. Stevens S, Ong J, Kim U, Eckhardt LA, Roeder RG. Role of OCA-B in 3'-IgH enhancer function. J Immunol 2000;164: 5306-5312. (Pubitemid 30305209)
7. Tang H, Sharp PA. Transcriptional regulation of the murine 3' IgH enhancer by OCT-2. Immunity 1999;11: 517-526.
8. Avet-Loiseau H, Brigaudeau C, Morineau N, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;24: 9-15. (Pubitemid 28544457)
9. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58: 5640-5645. (Pubitemid 29006396)
10. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-534. (Pubitemid 27299091)
11. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949. (Pubitemid 32012762)
12. Evans RP, Naber C, Steffler T, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140:295-302.
13. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327. (Pubitemid 35373567)
14. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin CancerRes 2007;13:994-999. (Pubitemid 46340378)
15. Advani AS, Lim K, Gibson S, et al. OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. Leuk Lym-phoma 2010;51:606-612.
16. Heckman CA, Duan H, Garcia PB, Boxer LM. Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 2006;25: 888-898. (Pubitemid 43237707)
17. Zhao C, Inoue J, Imoto I, et al. POU2AF1, an amplification target at 11q23, promotes growth ofmultiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17. Oncogene 2008;27:63-75.
18. Corcoran LM, Hasbold J, Dietrich W, et al. Differential requirement for OBF-1 during antibody-secreting cell differ-entiation. J Exp Med 2005;201:1385-1396. (Pubitemid 40664083)
19. Kallies A, Hasbold J, Tarlinton DM, et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expres-sion. J Exp Med 2004;200:967-977. (Pubitemid 39431122)
20. Kurabayashi H, Kubota K, Tsuchiya J, Murakami H, Tamura J, Naruse T. Prognostic value of morphological classifications and clinical variables in elderly and young patients with multiple myeloma. Ann Hematol 1999;78:19-23. (Pubitemid 29132428)